E-019 Initial post market experience with the pulserider intracranial stent. (22nd July 2018)

• Record Type: Journal Article
• Authors: de Macedo Rodrigues, K; Kan, P; Kuhn, A; Rex, D; Massari, F; Wakhloo, A; Puri, A
• Is Part Of: Journal of neurointerventional surgery. Volume 10(2018)Supplement 2
• Page Start: A57
• Page End: A57
• Publication Date: 2018-07-22
• Subjects: Nervous system -- Surgery -- Periodicals; Cerebrovascular disease -- Surgery -- Periodicals; 617.48
• DOI: 10.1136/neurintsurg-2018-SNIS.95
• Languages: English
• ISSNs: 1759-8478

Abstract

Abstract : Purpose: To show a two-centers initial post market experience with the use of a new intracranial stent specially designed for wide neck bifurcation aneurysm. Materials and methods: We retrospectively reviewed 6 consecutive cases of elective endovascular treatment of bifurcation aneurysms with the use of the PulseRider nitinol implant (Pulsar Vascular, Los Gatos, California) in addition to bare platinum embolization coils. A total of 6 patients (5 females) with 6 aneurysms (4 basilar, 2 anterior communicating artery) with age ranging from 51–67 years old were included. Dual anti-platelet therapy was started 5 days prior to the procedure. Three 'Y' shape and 3 'T' shape devices were utilized. Angiogram post device placement and coil placement were analyzed. A 6 month post procedure diagnostic cerebral angiogram was available for 2 patients. Results: Implant placement and subsequent aneurysm sac coil embolization successfully performed for all patients. Two patients had the resheatable implant retrieved for shape exchange. A 28% mean packing density was achieved. No periprocedural or immediate post procedural complications encountered. Two patients had a 6 month follow-up angiogram showing complete aneurysm occlusion. Conclusion/summary: Technical feasibility of the use of the PulseRider intracranial stent demonstrated in all 6 cases for endovascular embolization of wide neck bifurcation aneurysms. Limitations of this case series include small sample size, only 2 patients with a follow-up angiogram available and lack of long term clinical follow-up. Disclosures: K. de Macedo Rodrigues: None. P. Kan: 2; C; Stryker, Medtronic. A. Kuhn: None. D. Rex: None. F. Massari: None. A. Wakhloo: 1; C; Philips Healthcare. 2; C; Stryker Neurovascular. 3; C; Harvard Postgraduate Course, Miami Cardiovascular Institute. 4; C; InNeuroCo. A. Puri: 1; C; Stryker Neurovascular, Covidien. 2; C; Codman Neurovascular, Covidien. 4; C; InNeuroCo.